Rheumatism is an autoimmune disease that causes chronic inflammation and pain.
The inflammation can break down cartilage, adjacent bones, tendons and arteries. Also eyes and other organs can be affected. About one percent of the population suffer of the disease. It is more common among women than men. Drug market for the disease is estimated to be worth SEK 250 billion in year 2019.
Lipum develops a biological drug for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis that affects children. The idea is based on preclinical academic research at Umeå University and results from well-established models for inflammatory arthritis. Our new drug will stop the inflammation process and prevent destruction of the joints.
We are looking for partners and investors. Just fill in the form below and we will contact you for more information. You can also read more under Partners & Investors »